Actuate Therapeutics Inc
NASDAQ:ACTUBiotechnology
+$0.06 today
- Market cap
- $50.01M
- Beta
- 0.53
- P/E (TTM)
- -2.3
- EPS (TTM)
- -$0.92
Volume 0.03M
Average 0.16M
ACTU EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Actuate Therapeutics IncNASDAQ: ACTU
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$5.62M, compared with -$6.31M a year earlier. Trailing-twelve-month EBITDA was -$21.52M.
Context
- EBITDA grew in size in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the +11.7% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$5.62M-23.6% QoQ
- Last fiscal yearDec 2025
- -$22.21M+11.7% YoY
- LTMMar 2026
- -$21.52M+14.5% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +11.0% | +100.0% | +89.0 pp |
| 1 year | +11.7% | +100.0% | +88.3 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (22.21M) USD
- Year-over-year change
- +11.7%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22.21M) | +11.7% |
| FY2024 | 2024-12-31 | (25.16M) | -3.0% |
| FY2023 | 2023-12-31 | (24.43M) | -21.7% |
| FY2022 | 2022-12-31 | (20.08M) | — |
EBITDA vs competitors
How ACTU compares with its peers on the latest reported figures
- Peers report in different currencies, so EBITDA is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +14.5% is the 6th highest of 9, against a peer median of +22.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $449.13M USD | +489.9% | — | — | |
| LTM Mar 2026 | $14.89M USD | +121.1% | — | 27.2% | |
ACTUActuate Therapeutics Inc | LTM Mar 2026 | -$21.52M USD | +14.5% | — | — |
ELTXElicio Therapeutics, Inc. | LTM Mar 2026 | -$37.68M USD | +23.9% | — | — |
| LTM Mar 2026 | -$41.87M USD | +24.2% | — | 3650.0% | |
| LTM Mar 2026 | -CHF 63.08M CHF | -8.3% | — | — | |
| LTM Mar 2026 | -$75.99M USD | +22.0% | — | — | |
| LTM Mar 2026 | -$90.7M USD | +10.7% | — | — | |
| LTM Mar 2026 | -$116.42M USD | -1.3% | — | 632.1% | |
| Peer median (excluding ACTU) | — | +22.9% | — | 632.1% | |
Competitors are the stored peer set for ACTU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — |
| Research & Development | 16.39M | 21.71M | 18.68M | 10.29M |
| Selling, General & Admin | 3.82M | 3.27M | 6.48M | 12.2M |
| Operating Expenses | 20.21M | 24.97M | 25.16M | 22.5M |
| Depreciation & Amortization | 63.61K | 272.85K | 2.14M | 0 |
| EBITDA | (20.08M) | (24.43M) | (25.16M) | (22.21M) |
| EBITDA Margin | — | — | — | — |
| Operating Income | (20.21M) | (24.97M) | (25.16M) | (22.5M) |
| Operating Margin | — | — | — | — |
| Interest Income | 27.03K | 352.67K | 222.29K | 287.71K |
| Interest Expense | 16.2K | 43.64K | (18.72K) | 20.25K |
| Other Income / Expenses | 47.41K | 229.21K | (2.12M) | 267.46K |
| Income Before Tax | (20.16M) | (24.74M) | (27.28M) | (22.23M) |
| Pre-Tax Margin | — | — | — | — |
| Income Tax Expense | 0 | 0 | 800 | 0 |
| Net Income | (20.16M) | (24.74M) | (27.29M) | (22.23M) |
| Net Margin | — | — | — | — |
| EPS (Basic) | (1.34) | (1.65) | (3.26) | (1.06) |
| EPS (Diluted) | (1.34) | (1.65) | (3.26) | (1.06) |
| Weighted Avg Shares | 15.03M | 15.03M | 19.51M | 21.02M |
| Weighted Avg Shares (Diluted) | 15.03M | 15.03M | 19.51M | 21.02M |
Actuate Therapeutics Inc
NASDAQ:ACTU
Intrinsic Alpha fair value
Locked
Current Price
$2.09
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.